PwC upbeat on UK pharma M&A in 2023

30 January 2023

Analysis from financial services company PwC shows optimism for the year ahead in pharmaceutical M&A in the UK market.

Development stage biotech acquisitions by large pharma companies seeking to fill their pipelines will drive this activity, according to PwC, which is optimistic despite a disappointing 2022. Its latest UK M&A data shows that healthcare industries, including pharma and life sciences, M&A activity cooled down in 2022 from a record high in 2021.

Analysis of deal activity shows that the UK saw 234 deals across healthcare industries in 2022, compared to 365 for the previous year, a 36% decline. Further analysis shows that deal volume for the first half of the year was higher than the second half.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK